Oragenics Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company focused on brain-targeted therapeutics, has provided updates on its Phase IIa feasibility trial of ONP-002 for mild traumatic brain injury (mTBI), its regulatory path in the U.S., and its continued listing status on the NYSE American. These developments underscore the company's progress in advancing a potential first-in-class treatment for concussion and mTBI.
The company has dosed nine participants across three active Australian clinical sites: Alfred Health, Mackay, and Royal Adelaide Hospital. This multicenter approach is designed to gather safety and feasibility data for ONP-002, which is delivered via Oragenics' proprietary intranasal platform. The trial's progress is a critical step toward the company's goal of addressing a significant unmet medical need in neurological care.
On the regulatory front, Oragenics has received responses from the U.S. Food and Drug Administration (FDA) regarding its Type B meeting request briefing package submitted in July 2026. The company is currently reviewing these responses and remains on track to submit an Investigational New Drug (IND) application by the end of 2026. This submission is essential for initiating U.S.-based clinical trials, including the planned Phase 2b study.
In addition to clinical and regulatory updates, Oragenics disclosed that it received a deficiency letter from the NYSE American on Aug. 26, 2026, regarding stockholders' equity requirements under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. The company has 45 days from receipt of the letter to submit a plan to regain compliance. Oragenics intends to do so within the required timeframe. If the plan is accepted, the company would be able to maintain its listing during a cure period, subject to periodic review, with a compliance deadline of Feb. 25, 2028.
These updates are significant for investors and the medical community as they highlight Oragenics' ongoing efforts to navigate clinical development and regulatory processes. The successful completion of the Phase IIa trial and IND submission could position ONP-002 as a groundbreaking therapy for mTBI, which currently lacks approved treatments. Moreover, the company's intranasal delivery platform has broader potential applications for other neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders.
Oragenics' commitment to advancing ONP-002 is evident in its collaboration with Australian clinical sites and its proactive engagement with the FDA. The company's ability to address the NYSE American listing deficiency will be crucial for maintaining investor confidence and financial stability as it progresses through clinical milestones.
For more details on the full press release, visit https://nnw.fm/HZ5fb. For the latest news and updates regarding Oragenics, refer to the company's newsroom at https://nnw.fm/OGEN.
